Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) Shares Outstanding (Diluted Average) (2021 - 2025)

Rein Therapeutics filings provide 5 years of Shares Outstanding (Diluted Average) readings, the most recent being $25.4 million for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) rose 41.84% year-over-year to $25.4 million, compared with a TTM value of $25.4 million through Dec 2025, up 41.84%, and an annual FY2025 reading of $25.4 million, up 41.84% over the prior year.
  • Shares Outstanding (Diluted Average) hit $25.4 million in Q4 2025 for Rein Therapeutics, down from $26.4 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $90.5 million in Q2 2021, with the low at $4.4 million in Q4 2021.
  • Median Shares Outstanding (Diluted Average) over the past 5 years was $8.3 million (2024), compared with a mean of $20.2 million.
  • The sharpest move saw Shares Outstanding (Diluted Average) crashed 94.98% in 2022, then surged 377.04% in 2024.
  • Year by year, Shares Outstanding (Diluted Average) stood at $4.4 million in 2021, then increased by 2.23% to $4.5 million in 2022, then increased by 1.31% to $4.6 million in 2023, then soared by 290.09% to $17.9 million in 2024, then soared by 41.84% to $25.4 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $25.4 million, $26.4 million, and $23.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.